Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH-Reference-Cited by-同舟云学术

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of MASH

Published:2024-09-02 Issue:17 Volume:67 Page:14840-14851
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Vandyck Koen¹,McGowan David C.¹^ORCID,Luong Xuan G.²,Stevens Sarah K.²,Jekle Andreas²,Gupta Kusum²,Misner Dinah L.²,Chanda Sushmita²,Serebryany Vladimir²,Welch Michael²,Hu Haiyang³,Lv Zhidan³,Williams Caroline²,Maskos Klaus⁴,Lammens Alfred⁴,Stoycheva Antitsa D.²^ORCID,Lin Tse-I¹,Blatt Lawrence M.²,Beigelman Leonid N.²,Symons Julian A.²,Raboisson Pierre²,Deval Jerome²

Affiliation:

1. Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium

2. Aligos Therapeutics, Incorporated, 1 Corporate Drive, South San Francisco, California 94080, United States

3. Pharmaron, 6 Taihe Road, BDA, Beijing, 100176, P. R. China

4. Proteros Biostructures GmbH, Bunsenstraße 7a, 82152 Planegg-Martinsried, Germany

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.4c01029

Reference49 articles.

1. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort

2. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

3. A multisociety Delphi consensus statement on new fatty liver disease nomenclature

4. Nonalcoholic Steatohepatitis — Opportunities and Challenges

5. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention